1-3 of 3
Per Troellund Pedersen
Close
Sort by
Journal Articles

Outcome after 3 rd Line Treatment for Diffuse Large B-Cell Lymphoma: A Danish Population-Based Study

Ahmed Ludvigsen Al-Mashhadi, Lasse Hjort Jakobsen, Peter de Nully Brown, Anne Ortved Gang, Anne-Luise Thorsteinsson, Kaziwa Rasoul, Judith Melchior Heissmann, Michael Buch Tøstesen, Mette Nieman Christoffersen, Jelena Jelicic, Jennifer Bøgh Jørgensen, Troels Thomsen, Andriette Dessau-Arp, Andreas PH Andersen, Mikael Frederiksen, Per Troellund Pedersen, Michael Roost Clausen, Judit Jørgensen, Christian Bjørn Poulsen, Tarec Christoffer Christoffer El-Galaly, Thomas S. Larsen
Journal: Blood
Blood (2022) 140 (Supplement 1): 6706–6707.
https://doi.org/10.1182/blood-2022-167897
Published: 2022
Journal Articles

The Impact of the COVID-19 Pandemic on Quality of Life in Danish Patients with Multiple Myeloma; Results from an Ongoing Longitudinal National Survey

Louise Redder, Sören Möller, Anna Thit Johnsen, Mary Jarden, Christen lykkegaard Andersen, Henrik Frederiksen, Henrik Gregersen, Anja Klostergaard, Morten Saaby Steffensen, Per Troellund Pedersen, Maja Hinge, Mikael Frederiksen, Carsten Helleberg, Niels Abildgaard, Lene Kongsgaard Nielsen
Journal: Blood
Blood (2021) 138 (Supplement 1): 1638.
https://doi.org/10.1182/blood-2021-147707
Published: 2021
Journal Articles

Rituximab Maintenance after First Line Immunochemotherapy Improves Overall Survival in Patients with Follicular Lymphoma

Adam Vilmar, PhD MD, Bente Arboe, Par Josefsson, MD PhD, Christian Poulsen, Jacob Haaber Christensen, Judit Jørgensen, MD PhD, Paw Jensen, Jørn Starklint, Per Troellund Pedersen, Michael Pedersen, Peter de Nully Brown, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1781.
https://doi.org/10.1182/blood.V128.22.1781.1781
Published: 2016